Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, pharmacology and bioactivity of
disulfiram in antiretroviral treated HIV-infected adults. The investigators primary
hypothesis is that 3 days of disulfiram will result in an increase in HIV transcription in
CD4+ T-cells in patients on suppressive antiretroviral therapy (ART).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
amfAR, The Foundation for AIDS Research Monash University National Institute of Allergy and Infectious Diseases (NIAID)